NEW YORK (GenomeWeb News) – Sequenom President and CEO Harry Stylli said during the firm’s third-quarter conference call last night that the firm had filed a patent infringement suit against Ibis Biosciences for allegedly infringing three Sequenom patents related to nucleic acid analysis by mass spectrometry.
He offered few details about the suit, which was filed against the subsidiary of Carlsbad, Calif.-based Isis Pharmaceuticals yesterday in the US District Court in the District of Delaware. The filing does not yet appear on the court’s website.
Stylli alleged that Ibis’ T5000 Biosensor System and related technology infringes the Sequenom patents. He said the firm is seeking a permanent injunction that would bar the sale of the biosensor and related technologies as well as monetary damages.
Responding to a question during the call regarding legal expenses associated with the action against Ibis, Stylli said that those expected costs have already been built into the firm’s expectations for SG&A expenses. He declined to comment further on the cost, other than saying, “it’s not expected to be that much in the next 12 months. Frankly, we’re hoping that we’ll work out some kind of business solution.”
While Ibis is currently owned by Isis Pharmaceuticals, Abbott holds a nearly 20 percent stake in the subsidiary with an option to buy the remainder of Ibis through June 2009.